Developer docs
API playgroundTry for free, no card

Search company profiles

Cleara Biotech

Full company profile

uuid0002d4t

Namestring
Cleara Biotech
Legal namestring
Cleara Biotech B.V.
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Cleara Biotech B.V. is a private preclinical-stage biopharmaceutical R&D company headquartered in Utrecht, the Netherlands, founded in 2018 through a joint effort by Apollo Health Ventures and Dr. Peter de Keizer. The company develops D-amino acid peptide therapeutics designed to selectively eliminate p53-impaired ("scarred" or senescent) cells by binding multi-phosphorylated p53 (phosphorylated on residues including S46, T55 and S392) and inducing transcription-independent, mutation-site-agnostic apoptosis. Its lead development candidate, CL04183 (nominated in 2023), has demonstrated activity in 2D cell, 3D organoid and mouse in vivo models of metastatic colorectal cancer, triple-negative breast cancer and high-grade serous ovarian cancer, alongside preclinical signals in neurodegeneration, liver fibrosis and cardiovascular disease; CL04177 is a parallel optimized candidate. A proprietary companion-diagnostic multiplexing technology built around biomarkers such as pS392-p53 supports patient stratification, with >25% of mCRC, TNBC and HGSOC patients reported as biomarker-positive candidates.

The business model is pre-revenue R&D: Cleara has completed GLP-Tox studies in rats and non-human primates in 2025 with GMP-grade Drug Substance work completed, and is advancing toward a Clinical Trial Application. The company monetizes through Series-A financing or pharmaceutical partnering/licensing transactions rather than direct product sales, targeting large pharma counterparties for Phase 1a/1b execution and eventual commercialization. Its go-to-market is enterprise BD/licensing, supported by a senior clinical team (CMO Nick Sarlis, Chairman Angelos Stergiou) and an experienced technical operations function. Scientific foundation rests on long-term license and collaboration agreements with University Medical Center Utrecht (principal partner since 2018), UMC Groningen and Medical University of Graz, supplemented by two Dutch public-private initiatives (ZonMw/Health~Holland Voila/SMARTage in 2019 and TASCFORCE in 2022).

Short descriptiontext

Cleara Biotech is a private preclinical-stage biopharmaceutical company developing D-amino acid peptide therapeutics that selectively eliminate p53-impaired cancer and senescent cells, with lead candidate CL04183 advancing toward Phase 1 clinical trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersUtrecht, Netherlands
HQ citystring
Utrecht
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
senolytic therapeutics, cancer peptide development, biopharmaceutical R&D, D-amino acid peptides, companion diagnostic biomarkers
Industry3 codes
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Biopharmaceutical R&D
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pre-revenue R&D biotech
TypeLicensing Royalties
Description

Currently pre-revenue. Future revenue anticipated from Series-A financing or pharmaceutical partnering/licensing transactions as CL04183 progresses through Phase 1a/1b clinical trials in oncology, neurodegeneration, liver fibrosis, and cardiovascular indications.

clearabiotech.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Pricing details1 tier
1Quote-based / Not publicly disclosed
ModelOther
Notes

No commercial product pricing available; revenue model anticipates Series-A financing or pharma partnering/licensing.

clearabiotech.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Cleara Biotech is a preclinical biopharmaceutical R&D company developing proprietary D-amino acid peptide therapeutics that selectively eliminate p53-impaired ("scarred") cancer and senescent cells. Its lead development candidates, CL04183 and CL04177, induce transcription-independent, mutation-site-agnostic apoptosis in cancer cells with impaired p53 signaling and are being advanced for metastatic colorectal cancer, triple-negative breast cancer, high-grade serous ovarian cancer, and senescence-driven chronic indications (neurodegeneration, liver fibrosis, cardiovascular disease). The pipeline is paired with a proprietary pS392-p53 companion-diagnostic biomarker strategy for patient stratification.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • CL04183 induces 29% overall survival increase in geriatric mice (825 days at start of treatment) in third-party experiments
+4 more records
Product overview1 text field

Cleara Biotech B.V. is a private, preclinical-stage biopharmaceutical R&D company organised as a single platform-plus-candidates architecture: a core proprietary D-amino acid peptide development pipeline that designs and optimises compounds selectively eliminating p53-impaired (including mutant-p53) cancer and senescent cells, from which its named lead development candidates CL04183 and CL04177 are derived. CL04183 has been nominated as the lead Development Candidate and is supported in parallel by a proprietary biomarker companion-diagnostic multiplexing technology used to identify biomarker-positive patients. The company's historical research foundation is the FOXO4-DRI third-generation peptide, which preceded and informed the CL04177/CL04183 programme.

Product and service3 records
1CL04183
CategoryOncology peptide therapeutic
2CL04177
CategoryOncology peptide therapeutic
3Companion diagnostic biomarker technology
CategoryCompanion diagnostic / biomarker technology
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Company-wide due diligence by the public Dutch Governmental Agency RVO led to full endorsement of Cleara's program for preclinical development of CL04183, matched by financial support.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

In 2022, Cleara became the main industrial partner of the TASCFORCE PPP together with independent groups at UMC Utrecht to investigate the potential of CL04183 in (colon) cancer.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

In 2019, Cleara became the main industrial partner of the Voila/SMARTage Public Private Initiative, supporting senescence-related research and translation.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Principal long-term collaboration and license agreement executed in 2018. UMC Utrecht is also Cleara's scientific affiliation. Dr. Peter de Keizer is an associate professor at UMC Utrecht. Independent groups at UMC Utrecht collaborate with Cleara on the TASCFORCE PPP for colon cancer.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Supporting collaboration and license agreement executed in 2018. UMC Groningen collaborates on senescence research underpinning Cleara's programs.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Supporting collaboration and license agreement executed in 2018. Prof. Tobias Madl (Head of structural biology and scientific co-founder at Cleara) leads structural biology work at the Medical University of Graz.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage senolytic company developing small-molecule therapies (UBX0101, UBX1325) that selectively eliminate senescent cells for age-related diseases. Most directly comparable to Cleara's senolytic approach targeting senescent and p53-impaired cells, though focused on ophthalmology and musculoskeletal indications.

TypeDirect peer
Description

Clinical-stage oncology company developing eprenetapopt (APR-246), a small-molecule reactivator of mutant p53 in tumors. Closest mechanistic peer to Cleara in the p53-targeted oncology space, though using a transcription-dependent reactivation approach rather than Cleara's transcription-independent peptide strategy.

TypeDirect peer
Description

Clinical-stage precision oncology company developing small molecules (PC14586, zoldonrasib) that restore wild-type p53 function in p53 Y220C-mutant cancers. Directly comparable oncology mechanism targeting p53 dysfunction, though focused on a specific hotspot mutation versus Cleara's mutation-site-agnostic peptide.

4Rubedo Life Sciences
TypeDirect peer
Description

Preclinical-stage senolytic company developing selective small molecules that target senescent cells implicated in age-related diseases. Closely comparable emerging senolytic peer, although Rubedo focuses on small-molecule chemistry rather than Cleara's D-amino acid peptide platform.

TypeEmerging player
Description

Preclinical-stage company developing a senolytic gene therapy platform that selectively eliminates senescent cells via apoptosis induction. Comparable senescence-targeting approach but using a gene-therapy delivery mechanism rather than Cleara's peptide platform.

TypeEmerging player
Description

Clinical-stage biotech developing therapeutics that target the biological drivers of aging, including senescence-related pathways, with an IND-stage pipeline for age-related conditions. Comparable aging/senescence therapeutic area focus, though BioAge uses small-molecule and antibody approaches.

7AgeX Therapeutics
TypeEmerging player
Description

Biotechnology company developing therapies based on cellular senescence and regenerative biology for age-related diseases. Operates in the same cellular senescence therapeutic space as Cleara, though currently focused on pluripotent stem cell-derived and telomerase-based programs.

TypeBroad incumbent
Description

Established Danish clinical-stage biopharmaceutical company specializing in peptide-based therapeutics across metabolic and rare disease indications. Comparable peptide drug development platform and modality, though targeting metabolic rather than oncology/aging indications.

9PeptiDream
TypeBroad incumbent
Description

Japanese clinical-stage company with a proprietary Peptide Discovery Platform System (PDPS) for identifying non-standard peptide therapeutics. Comparable peptide drug discovery platform, though partnered across multiple therapeutic areas and used primarily as a discovery engine for partners.

TypeBroad incumbent
Description

Clinical-stage biotech developing bicyclic peptide (bicycles) therapeutics for oncology, with lead programs in cancer cell-killing and immune cell-engaging modalities. Closest broad incumbent in synthetic constrained peptide therapeutics with comparable clinical-stage oncology focus.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cleara Biotech

Biopharmaceutical R&Dclearabiotech.com

Cleara Biotech is a private preclinical-stage biopharmaceutical company developing D-amino acid peptide therapeutics that selectively eliminate p53-impaired cancer and senescent cells, with lead candidate CL04183 advancing toward Phase 1 clinical trials.

What Cleara Biotech does

Cleara Biotech B.V. is a private preclinical-stage biopharmaceutical R&D company headquartered in Utrecht, the Netherlands, founded in 2018 through a joint effort by Apollo Health Ventures and Dr. Peter de Keizer. The company develops D-amino acid peptide therapeutics designed to selectively eliminate p53-impaired ("scarred" or senescent) cells by binding multi-phosphorylated p53 (phosphorylated on residues including S46, T55 and S392) and inducing transcription-independent, mutation-site-agnostic apoptosis. Its lead development candidate, CL04183 (nominated in 2023), has demonstrated activity in 2D cell, 3D organoid and mouse in vivo models of metastatic colorectal cancer, triple-negative breast cancer and high-grade serous ovarian cancer, alongside preclinical signals in neurodegeneration, liver fibrosis and cardiovascular disease; CL04177 is a parallel optimized candidate. A proprietary companion-diagnostic multiplexing technology built around biomarkers such as pS392-p53 supports patient stratification, with >25% of mCRC, TNBC and HGSOC patients reported as biomarker-positive candidates.

The business model is pre-revenue R&D: Cleara has completed GLP-Tox studies in rats and non-human primates in 2025 with GMP-grade Drug Substance work completed, and is advancing toward a Clinical Trial Application. The company monetizes through Series-A financing or pharmaceutical partnering/licensing transactions rather than direct product sales, targeting large pharma counterparties for Phase 1a/1b execution and eventual commercialization. Its go-to-market is enterprise BD/licensing, supported by a senior clinical team (CMO Nick Sarlis, Chairman Angelos Stergiou) and an experienced technical operations function. Scientific foundation rests on long-term license and collaboration agreements with University Medical Center Utrecht (principal partner since 2018), UMC Groningen and Medical University of Graz, supplemented by two Dutch public-private initiatives (ZonMw/Health~Holland Voila/SMARTage in 2019 and TASCFORCE in 2022).

Cleara Biotech firmographics

Firmographics
Name
Cleara Biotech
Legal name
Cleara Biotech B.V.
Website
https://clearabiotech.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Short description
Cleara Biotech is a private preclinical-stage biopharmaceutical company developing D-amino acid peptide therapeutics that selectively eliminate p53-impaired cancer and senescent cells, with lead candidate CL04183 advancing toward Phase 1 clinical trials.
Ownership category
akta.pro rank

Cleara Biotech industry classification

Industry
Product category
Biopharmaceutical R&D
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Senolytic therapeutics
  • Cancer peptide development
  • Biopharmaceutical R&D
  • D-amino acid peptides
  • Companion diagnostic biomarkers

Where Cleara Biotech is headquartered

Location

Headquarters

HQ city
Utrecht
HQ country
Netherlands
HQ region
Europe

Offices1 record

Markets served

Cleara Biotech business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Pre-revenue R&D biotech: Currently pre-revenue. Future revenue anticipated from Series-A financing or pharmaceutical partnering/licensing transactions as CL04183 progresses through Phase 1a/1b clinical trials in oncology, neurodegeneration, liver fibrosis, and cardiovascular indications.

Pricing tiers

ModelBillingPrice
Other—Quote-based / Not publicly disclosed

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Cleara Biotech product offering

Product offering

Core offering

Cleara Biotech is a preclinical biopharmaceutical R&D company developing proprietary D-amino acid peptide therapeutics that selectively eliminate p53-impaired ("scarred") cancer and senescent cells. Its lead development candidates, CL04183 and CL04177, induce transcription-independent, mutation-site-agnostic apoptosis in cancer cells with impaired p53 signaling and are being advanced for metastatic colorectal cancer, triple-negative breast cancer, high-grade serous ovarian cancer, and senescence-driven chronic indications (neurodegeneration, liver fibrosis, cardiovascular disease). The pipeline is paired with a proprietary pS392-p53 companion-diagnostic biomarker strategy for patient stratification.

Product overview

Cleara Biotech B.V. is a private, preclinical-stage biopharmaceutical R&D company organised as a single platform-plus-candidates architecture: a core proprietary D-amino acid peptide development pipeline that designs and optimises compounds selectively eliminating p53-impaired (including mutant-p53) cancer and senescent cells, from which its named lead development candidates CL04183 and CL04177 are derived. CL04183 has been nominated as the lead Development Candidate and is supported in parallel by a proprietary biomarker companion-diagnostic multiplexing technology used to identify biomarker-positive patients. The company's historical research foundation is the FOXO4-DRI third-generation peptide, which preceded and informed the CL04177/CL04183 programme.

Differentiator

Problem solved

Functional benefit

Products and services

  • CL04183
  • CL04177
  • Companion diagnostic biomarker technology

Quantifiable outcome

  • CL04183 induces 29% overall survival increase in geriatric mice (825 days at start of treatment) in third-party experiments
  • +4 more outcomes

Companies that use Cleara Biotech

Customer profile

Segments3 records

Ideal customer profiles2 records

Cleara Biotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Cleara Biotech partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and flagship.

  • RVO (Dutch Governmental Agency)coreStrategic or Co-development Partner · 1 January 2023Company-wide due diligence by the public Dutch Governmental Agency RVO led to full endorsement of Cleara's program for preclinical development of CL04183, matched by financial support.
  • ZonMw / Health~Holland Public Private Initiative 'TASCFORCE'coreStrategic or Co-development Partner · 1 January 2022In 2022, Cleara became the main industrial partner of the TASCFORCE PPP together with independent groups at UMC Utrecht to investigate the potential of CL04183 in (colon) cancer.
  • ZonMw / Health~Holland Public Private Initiative 'Voila/SMARTage'coreStrategic or Co-development Partner · 1 January 2019In 2019, Cleara became the main industrial partner of the Voila/SMARTage Public Private Initiative, supporting senescence-related research and translation.
  • UMC Utrecht (University Medical Center Utrecht)flagshipStrategic or Co-development Partner · 1 January 2018Principal long-term collaboration and license agreement executed in 2018. UMC Utrecht is also Cleara's scientific affiliation. Dr. Peter de Keizer is an associate professor at UMC Utrecht. Independent groups at UMC Utrecht collaborate with Cleara on the TASCFORCE PPP for colon cancer.
  • UMC Groningen (Dr. Marco Demaria)coreStrategic or Co-development Partner · 1 January 2018Supporting collaboration and license agreement executed in 2018. UMC Groningen collaborates on senescence research underpinning Cleara's programs.
  • Medical University of Graz (Prof. Tobias Madl)coreStrategic or Co-development Partner · 1 January 2018Supporting collaboration and license agreement executed in 2018. Prof. Tobias Madl (Head of structural biology and scientific co-founder at Cleara) leads structural biology work at the Medical University of Graz.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Cleara Biotech competitors and assessment

Company assessment

Direct peers

  • Unity Biotechnology: Clinical-stage senolytic company developing small-molecule therapies (UBX0101, UBX1325) that selectively eliminate senescent cells for age-related diseases. Most directly comparable to Cleara's senolytic approach targeting senescent and p53-impaired cells, though focused on ophthalmology and musculoskeletal indications.
  • Aprea Therapeutics: Clinical-stage oncology company developing eprenetapopt (APR-246), a small-molecule reactivator of mutant p53 in tumors. Closest mechanistic peer to Cleara in the p53-targeted oncology space, though using a transcription-dependent reactivation approach rather than Cleara's transcription-independent peptide strategy.
  • PMV Pharma: Clinical-stage precision oncology company developing small molecules (PC14586, zoldonrasib) that restore wild-type p53 function in p53 Y220C-mutant cancers. Directly comparable oncology mechanism targeting p53 dysfunction, though focused on a specific hotspot mutation versus Cleara's mutation-site-agnostic peptide.
  • Rubedo Life Sciences: Preclinical-stage senolytic company developing selective small molecules that target senescent cells implicated in age-related diseases. Closely comparable emerging senolytic peer, although Rubedo focuses on small-molecule chemistry rather than Cleara's D-amino acid peptide platform.

Emerging players

  • Oisin Biotechnologies: Preclinical-stage company developing a senolytic gene therapy platform that selectively eliminates senescent cells via apoptosis induction. Comparable senescence-targeting approach but using a gene-therapy delivery mechanism rather than Cleara's peptide platform.
  • BioAge Labs: Clinical-stage biotech developing therapeutics that target the biological drivers of aging, including senescence-related pathways, with an IND-stage pipeline for age-related conditions. Comparable aging/senescence therapeutic area focus, though BioAge uses small-molecule and antibody approaches.
  • AgeX Therapeutics: Biotechnology company developing therapies based on cellular senescence and regenerative biology for age-related diseases. Operates in the same cellular senescence therapeutic space as Cleara, though currently focused on pluripotent stem cell-derived and telomerase-based programs.

Broad incumbents

  • Zealand Pharma: Established Danish clinical-stage biopharmaceutical company specializing in peptide-based therapeutics across metabolic and rare disease indications. Comparable peptide drug development platform and modality, though targeting metabolic rather than oncology/aging indications.
  • PeptiDream: Japanese clinical-stage company with a proprietary Peptide Discovery Platform System (PDPS) for identifying non-standard peptide therapeutics. Comparable peptide drug discovery platform, though partnered across multiple therapeutic areas and used primarily as a discovery engine for partners.
  • Bicycle Therapeutics: Clinical-stage biotech developing bicyclic peptide (bicycles) therapeutics for oncology, with lead programs in cancer cell-killing and immune cell-engaging modalities. Closest broad incumbent in synthetic constrained peptide therapeutics with comparable clinical-stage oncology focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Cleara Biotech social profiles

Digital presence

Cleara Biotech compliance and trust

Trust signal

Compliance1 record

Cleara Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cleara Biotech leadership team

Management profile

Number of profiles

Profiles15 records

Cleara Biotech funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cleara Biotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cleara Biotech

What does Cleara Biotech do?

Cleara Biotech is a preclinical biopharmaceutical R&D company developing proprietary D-amino acid peptide therapeutics that selectively eliminate p53-impaired ("scarred") cancer and senescent cells. Its lead development candidates, CL04183 and CL04177, induce transcription-independent, mutation-site-agnostic apoptosis in cancer cells with impaired p53 signaling and are being advanced for metastatic colorectal cancer, triple-negative breast cancer, high-grade serous ovarian cancer, and senescence-driven chronic indications (neurodegeneration, liver fibrosis, cardiovascular disease). The pipeline is paired with a proprietary pS392-p53 companion-diagnostic biomarker strategy for patient stratification.

Is Cleara Biotech a public or private company?

Cleara Biotech is a private company. It is classified as venture growth investor backed and is currently operating.

When was Cleara Biotech founded?

Cleara Biotech was founded in 2018. It employs 1 to 10 people.

Where is Cleara Biotech based?

Cleara Biotech is headquartered in Utrecht, Netherlands, in the Europe region.

How does Cleara Biotech make money?

One revenue line is on record: pre-revenue R&D biotech.

Who are Cleara Biotech's main competitors?

Direct peers on record are Unity Biotechnology, Aprea Therapeutics, PMV Pharma and Rubedo Life Sciences. Emerging players are Oisin Biotechnologies, BioAge Labs and AgeX Therapeutics. Broad incumbents are Zealand Pharma, PeptiDream and Bicycle Therapeutics.

Does Cleara Biotech have an API?

No public API is recorded for Cleara Biotech.

What industry is Cleara Biotech in?

Cleara Biotech's product category is Biopharmaceutical R&D. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogCLEARA Biotech Appoints Nicholas J. Sarlis, MD, PhD as Chief Medical Officer and Head of Clinical DevelopmentCLEARA Biotech appointed Dr. Nicholas J. Sarlis as Chief Medical Officer and Head of Clinical Development. He brings over 25 years of experience, including roles at Incyte, Sanofi, and Amplity Health. The company's lead program, CL04183, targets scarred metastatic cancer.Silicon CanalsDutch-based Cleara raises €2.58M to develop therapies against late-stage cancer, chronic diseasesUtrecht-based Cleara announced it raised €2.58M in a Seed round of funding to develop therapies for late-stage cancer and chronic diseases. The funding, led by Apollo Health Ventures, will support the advancement of Cleara's clinical development pipeline and management team. Cleara aims to create precision medicine tools targeting scarred cellular senescence using its two lead compounds, CL04177 and CL04183, with plans to enter clinical trials by 2024.BioSpaceCleara Biotech Raises $2.5 Million in Seed Financing to Advance FOXO4-Therapeutics Pipeline for Treating Cancer and Chronic DiseasesCLEARA Biotech B.V. closed a $2.5 million seed financing round led by Apollo Health Ventures to advance its FOXO4-therapeutics pipeline for cancer and chronic diseases. The company also appointed Dr. Angelos Stergiou as Chairman of the Board to support its strategic growth and regulatory efforts in the U.S. and EU. These funds will be used to progress lead compounds CL04177 and CL04183 toward clinical development.